Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Genetics of Mucopolysaccharidosis Type IV Medication

  • Author: Nancy E Braverman, MS, MD; Chief Editor: Maria Descartes, MD  more...
 
Updated: Mar 24, 2014
 

Medication Summary

Elosulfase alfa (Vimizim; BioMarin Pharmaceutical, Inc) was approved by the FDA in February 2014 for patients with Morquio A syndrome (mucopolysaccharidosis Type IVA [MPS IVA]). Approval was supported by a 24-week, randomized, clinical trial involving 176 patients. The primary endpoint of the trial, change in 6-minute walk distance at 24 weeks, was statistically significant in patients who received weekly elosulfase alfa 2 mg/kg IV infusions. The walking distance improved in the elosulfase alfa group with a mean increase of 22.5 meters over placebo. Walking ability was sustained in patients who continued weekly elosulfase alfa for an additional 48 weeks.[7]

Ancillary treatments include nonsteroidal anti-inflammatory drugs (NSAIDs) for joint pain, antibiotics for pulmonary infections, and oxygen for pulmonary compromise or obstructive sleep apnea.

Next

Enzymes

Class Summary

Enzyme replacement therapy may provide clinically important benefits.

Elosulfase alfa (Vimizim)

 

Elosulfase alfa replaces deficient enzyme N-acetylgalactosamine-6 sulfatase (GALNS) to minimize progressive multisystemic manifestations of Morquio A syndrome. The enzyme is taken up into the lysosomes and increases catabolism of GAGs KS and C6S.

Previous
 
 
Contributor Information and Disclosures
Author

Nancy E Braverman, MS, MD Associate Professor, Department of Human Genetics, McGill University

Nancy E Braverman, MS, MD is a member of the following medical societies: Alpha Omega Alpha, Society for Inherited Metabolic Disorders, Society for the Study of Inborn Errors of Metabolism, American Society of Human Genetics

Disclosure: Nothing to disclose.

Coauthor(s)

Julie Hoover-Fong, MD, PhD, FACMG Associate Professor, Director, Greenberg Center for Skeletal Dysplasias, McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine

Julie Hoover-Fong, MD, PhD, FACMG is a member of the following medical societies: American College of Medical Genetics and Genomics, International Skeletal Dysplasia Society, American Society of Human Genetics

Disclosure: Nothing to disclose.

Michael C Ain, MD Associate Professor, Departments of Neurosurgery and General Surgery, Division of Pediatric Orthopaedic Surgery, Johns Hopkins University School of Medicine

Michael C Ain, MD is a member of the following medical societies: American Academy of Orthopaedic Surgeons, American Orthopaedic Association, Scoliosis Research Society, Pediatric Orthopaedic Society of North America

Disclosure: Nothing to disclose.

Shunji Tomatsu, MD, PhD Professor, Department of Pediatrics, Saint Louis University School of Medicine

Shunji Tomatsu, MD, PhD is a member of the following medical societies: National MPS Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Margaret M McGovern, MD, PhD Professor and Chair of Pediatrics, Stony Brook University School of Medicine

Margaret M McGovern, MD, PhD is a member of the following medical societies: American Academy of Pediatrics, American Society of Human Genetics

Disclosure: Nothing to disclose.

Chief Editor

Maria Descartes, MD Professor, Department of Human Genetics and Department of Pediatrics, University of Alabama at Birmingham School of Medicine

Maria Descartes, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Medical Genetics and Genomics, American Medical Association, American Society of Human Genetics, Society for Inherited Metabolic Disorders, International Skeletal Dysplasia Society, Southeastern Regional Genetics Group

Disclosure: Nothing to disclose.

Additional Contributors

Karl S Roth, MD Retired Professor and Chair, Department of Pediatrics, Creighton University School of Medicine

Karl S Roth, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American College of Nutrition, American Pediatric Society, American Society for Nutrition, American Society of Nephrology, Association of American Medical Colleges, Medical Society of Virginia, New York Academy of Sciences, Sigma Xi, Society for Pediatric Research, Southern Society for Pediatric Research

Disclosure: Nothing to disclose.

References
  1. Montano AM, Tomatsu S, Gottesman GS, Smith M, Orii T. International Morquio A Registry: clinical manifestation and natural course of Morquio A disease. J Inherit Metab Dis. 2007 Apr. 30(2):165-74. [Medline].

  2. Tomatsu S, Montano AM, Ohashi A, et al. Enzyme replacement therapy in a murine model of Morquio A syndrome. Hum Mol Genet. 2008 Mar 15. 17(6):815-24. [Medline].

  3. Montano AM, Tomatsu S, Brusius A, Smith M, Orii T. Growth charts for patients affected with Morquio A disease. Am J Med Genet A. 2008 May 15. 146A(10):1286-95. [Medline].

  4. Dvorak-Ewell M, Wendt D, Hague C, Christianson T, Koppaka V, Crippen D, et al. Enzyme replacement in a human model of mucopolysaccharidosis IVA in vitro and its biodistribution in the cartilage of wild type mice. PLoS One. 2010 Aug 16. 5(8):e12194. [Medline]. [Full Text].

  5. Ain MC, Chaichana KL, Schkrohowsky JG. Retrospective study of cervical arthrodesis in patients with various types of skeletal dysplasia. Spine. 2006 Mar 15. 31(6):E169-74. [Medline].

  6. Tobias JD. Anesthetic care for the child with Morquio syndrome: general versus regional anesthesia. J Clin Anesth. 1999 May. 11(3):242-6. [Medline].

  7. A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome). NCT01275066. ClinicalTrials.gov. Available at http://clinicaltrials.gov/ct2/show/study/NCT01275066. Accessed: February 20, 2014.

  8. Institute for Clinical Systems Improvement (ICSI). Immunizations. Bloomington, MN: Institute for Clinical Systems Improvement (ICSI); 2008.

  9. Cunningham M, Cox EO. Hearing assessment in infants and children: recommendations beyond neonatal screening. Pediatrics. 2003 Feb. 111(2):436-40. [Medline].

  10. Ashworth JL, Biswas S, Wraith E, Lloyd IC. Mucopolysaccharidoses and the eye. Surv Ophthalmol. 2006 Jan-Feb. 51(1):1-17. [Medline].

  11. Baehner F, Schmiedeskamp C, Krummenauer F, et al. Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis. 2005. 28(6):1011-7. [Medline].

  12. Callahan JW. Molecular basis of GM1 gangliosidosis and Morquio disease, type B. Structure-function studies of lysosomal beta-galactosidase and the non-lysosomal beta-galactosidase-like protein. Biochim Biophys Acta. 1999 Oct 8. 1455(2-3):85-103. [Medline].

  13. Defraia E, Marinelli A, Antonini A, Giuntini V. Abnormal mandibular growth after craniovertebral surgery in Morquio syndrome type A. Angle Orthod. 2005 May. 75(3):461-4. [Medline].

  14. Factor SM, Biempica L, Goldfischer S. Coronary intimal sclerosis in Morquio's syndrome. Virchows Arch A Pathol Anat Histol. 1978 Aug 4. 379(1):1-10. [Medline].

  15. Funderburgh JL. Keratan sulfate: structure, biosynthesis, and function. Glycobiology. 2000 Oct. 10(10):951-8. [Medline].

  16. Hinek A, Zhang S, Smith AC, Callahan JW. Impaired elastic-fiber assembly by fibroblasts from patients with either Morquio B disease or infantile GM1-gangliosidosis is linked to deficiency in the 67-kD spliced variant of beta-galactosidase. Am J Hum Genet. 2000 Jul. 67(1):23-36. [Medline]. [Full Text].

  17. Hoffmann B, Mayatepek E. Neurological manifestations in lysosomal storage disorders - from pathology to first therapeutic possibilities. Neuropediatrics. 2005 Oct. 36(5):285-9. [Medline].

  18. Holzgreve W, Grobe H, von Figura K, et al. Morquio syndrome: clinical findings in 11 patients with MPS IVA and 2 patients with MPS IVB. Hum Genet. 1981. 57(4):360-5. [Medline].

  19. Hoogerbrugge PM, Brouwer OF, Bordigoni P, et al. Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation. Lancet. 1995 Jun 3. 345(8962):1398-402. [Medline].

  20. Hopwood JJ, Morris CP. The mucopolysaccharidoses. Diagnosis, molecular genetics and treatment. Mol Biol Med. 1990 Oct. 7(5):381-404. [Medline].

  21. Laradi S, Tukel T, Khediri S, et al. Mucopolysaccharidosis type IV: N-acetylgalactosamine-6-sulfatase mutations in Tunisian patients. Mol Genet Metab. 2006 Mar. 87(3):213-8. [Medline].

  22. Leslie T, Siddiqui MA, Aitken DA, et al. Morquio syndrome: electron microscopic findings. Br J Ophthalmol. 2005 Jul. 89(7):925-6. [Medline].

  23. McKusick VA. The nosology of the mucopolysaccharidoses. Am J Med. 1969 Nov. 47(5):730-47. [Medline].

  24. Meikle PJ, Ranieri E, Simonsen H, et al. Newborn screening for lysosomal storage disorders: clinical evaluation of a two-tier strategy. Pediatrics. 2004 Oct. 114(4):909-16. [Medline]. [Full Text].

  25. Millington DS. Newborn screening for lysosomal storage disorders. Clin Chem. 2005 May. 51(5):808-9. [Medline]. [Full Text].

  26. Natowicz MR, Short MP, Wang Y, et al. Clinical and biochemical manifestations of hyaluronidase deficiency. N Engl J Med. 1996 Oct 3. 335(14):1029-33. [Medline].

  27. Nelson J. Incidence of the mucopolysaccharidoses in Northern Ireland. Hum Genet. 1997 Dec. 101(3):355-8. [Medline].

  28. Neufeld EF. Lysosomal storage diseases. Annu Rev Biochem. 1991. 60:257-80. [Medline].

  29. Neufeld EF, Muenzer J. The mucopolysaccharidoses. Scriver CR, Beaudet AL, Sly WS, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York, NY: McGraw-Hill, Inc; 2001: 3421-52.

  30. Northover H, Cowie RA, Wraith JE. Mucopolysaccharidosis type IVA (Morquio syndrome): a clinical review. J Inherit Metab Dis. 1996. 19(3):357-65. [Medline].

  31. Resnick D. Osteochondrodysplasias, dysostoses, chromosomal aberrations, mucopolysaccharidoses, mucolipidoses and other skeletal dysplasias. Diagnosis of Bone and Joint Disorders V-5. Philadelphia, PA: WB Saunders Co; 1988. 3501-7.

  32. Rigante D, Antuzzi D, Ricci R, Segni G. Cervical myelopathy in mucopolysaccharidosis type IV. Clin Neuropathol. 1999 Mar-Apr. 18(2):84-6. [Medline].

  33. Shinhar SY, Zablocki H, Madgy DN. Airway management in mucopolysaccharide storage disorders. Arch Otolaryngol Head Neck Surg. 2004 Feb. 130(2):233-7. [Medline].

  34. Sukegawa K, Nakamura H, Kato Z, et al. Biochemical and structural analysis of missense mutations in N- acetylgalactosamine-6-sulfate sulfatase causing mucopolysaccharidosis IVA phenotypes. Hum Mol Genet. 2000 May 22. 9(9):1283-90. [Medline]. [Full Text].

  35. Suzuki Y, Oshima A, Nanba E. Beta-galactosidase deficiency (beta-gGalactosidosis): GM1 gangliosidosis and Morquio B disease. Scriver CR, Beaudet AL, Sly WS, eds. The Metabolic and Molecular Basis of Inherieted Disease. 8th ed. Philadelphia, PA: McGraw-Hill, Inc; 2001. 3775-809.

  36. Tomatsu S, Gutierrez M, Nishioka T, et al. Development of MPS IVA mouse (Galnstm(hC79S.mC76S)slu) tolerant to human N-acetylgalactosamine-6-sulfate sulfatase. Hum Mol Genet. 2005 Nov 15. 14(22):3321-35. [Medline].

  37. Tomatsu S, Montano AM, Nishioka T, et al. Mutation and polymorphism spectrum of the GALNS gene in mucopolysaccharidosis IVA (Morquio A). Hum Mutat. 2005 Dec. 26(6):500-12. [Medline].

  38. Tomatsu S, Okamura K, Taketani T, et al. Development and testing of new screening method for keratan sulfate in mucopolysaccharidosis IVA. Pediatr Res. 2004 Apr. 55(4):592-7. [Medline].

  39. Tomatsu S, Orii KO, Vogler C, et al. Mouse model of N-acetylgalactosamine-6-sulfate sulfatase deficiency (Galns-/-) produced by targeted disruption of the gene defective in Morquio A disease. Hum Mol Genet. 2003 Dec 15. 12(24):3349-58. [Medline].

  40. Tomatsu S, Vogler C, Montano AM, et al. Murine model (Galns(tm(C76S)slu)) of MPS IVA with missense mutation at the active site cysteine conserved among sulfatase proteins. Mol Genet Metab. 2007 Jul. 91(3):251-8. [Medline].

  41. Ullrich K. Screening for lysosomal disorders. Eur J Pediatr. 1994. 153(7 Suppl 1):S38-43. [Medline].

  42. Urban Z, Boyd CD. Elastic-fiber pathologies: primary defects in assembly and secondary disorders in transport and delivery. Am J Hum Genet. 2000 Jul. 67(1):4-7. [Medline].

  43. Yuen M, Fensom AH. Diagnosis of classical Morquio's disease: N-acetylgalactosamine 6-sulphate sulphatase activity in cultured fibroblasts, leukocytes, amniotic cells and chorionic villi. J Inherit Metab Dis. 1985. 8(2):80-6. [Medline].

Previous
Next
 
Lateral view of spine in a child aged 8 years and 7 months. This radiograph shows advanced platyspondyly, irregularity, and anterior beaking of vertebral bodies characteristic of dysostosis multiplex. Note also the gibbus deformity and lordosis, which are characteristic of Morquio syndrome.
Cervical spine, flexion and extension views, in a child aged 5 years and 11 months. These flexion and extension images depict anterior and posterior subluxation, respectively, of the atlas secondary to odontoid hypoplasia.
Bilateral lower extremity views in a patient aged 22 years and 6 months. Metaphyseal irregularities and the characteristic genu valgus deformity are easily observed in this image.
Bilateral hand radiographs in a patient aged 22 years and 6 months. Note the tapering of the proximal portion of metacarpals 2 through 5 and small irregular carpal bones. The epiphyseal involvement characteristic of Morquio syndrome is exemplified by the tapered irregular distal radius and ulna. Overall, the bones are osteopenic with cortical thinning.
Upper extremities in a child aged 6 years and 11 months. Note the irregular epiphyses and widened metaphyses. Cortical thinning and mild widening of the diaphysis of the humerus are visible.
Multiple abnormalities are present in the pelvis, including dysplastic femoral heads and oblique acetabular roof with coxa valgus deformity. Flared iliac wings usually observed in Morquio syndrome are not well represented in this radiograph.
Anteroposterior view of the chest in a child aged 8 years and 4 months with Morquio syndrome. To reference the relatively small size of this chest, this patient's vital capacity was 500 cc, but the expected value based on height and weight was 1400 cc. Widened metaphyses and irregular epiphyses of the humeri and generalized platyspondyly are present. Oar-shaped ribs (widening ribs anteriorly and narrowing at the vertebrae) are easily observed and are another key characteristic of dysostosis multiplex.
Defects in keratan sulfate (KS) degradation resulting in Morquio syndrome.
The individual on the front of the scooter is 19 years old and has Morquio syndrome. Her friend on the back is an average-stature 10 year old without Morquio syndrome. On the driver, note the enlargement at the knees and the wrist deformity. Also, note the successful adaptation of the scooter to ambulate.
Note the short trunk and protuberant rib structure in this child with Morquio syndrome. More importantly, notice that Morquio syndrome is not preventing this child from being active and fishing.
Table 1. Clinical and Biochemical Features Distinguishing the Mucopolysaccharidoses and Morquio Syndrome (Mucopolysaccharidosis Type IV)
MPS TypeEponymDeficient



Enzyme



Neuro-degenerationSomatic Features*Corneal CloudingBone / Joint AbnormalityMucopoly-saccharide Stored
IHHurlerα -iduronidase++++++++++Dermatan sulfate (DS), heparan sulfate (HS)
IH/SHurler-Scheieα -iduronidase++++++DS, HS
ISScheieα -iduronidase+++DS, HS
IIHunterIduronidase sulfatase++++++DS, HS
III † Sanfilippo AHeparan sulfatase+++++HS
Sanfilippo BN -acetylgluco-saminidase+++++HS
Sanfilippo CAcetyl CoA glucosamine acetyltransferase+++++HS
Sanfilippo DN -acetylglucosamine-6-sulfatase+++++HS
IVMorquio AGalactosamine-6-sulfatase++ / —+ / ++ / +++KS, chondroitin sulfate (CS)
Morquio Bβ -galactosidase++ / —+ / ++ / +++KS, CS
VNonexistent
VIMaroteaux-LamyN -acetylhexosamine-4-sulfatase++++DS
VIISly ‡ β -glucuronidase++++++DS, HS, CS
IXHyaluronidase deficiency § Hyaluronidase+Hyaluron
*Somatic features include organomegaly and facial coarsening.



† Eye findings may include cherry red spots.



‡ Severity widely varies; no neurologic degeneration is noted, but mental retardation is possible.



§ Only one patient has been described whose major features were periarticular soft tissue masses.



Table 2. Enzyme Replacement Therapy for the Mucopolysaccharidoses
MPS TypeDisease NameEnzyme DeficiencyERTCompanyClinical Use
IHurlerα -iduronidaselaronidase



(Aldurazyme)



GenzymeIn use
IH/SHurler-Scheieα -iduronidaselaronidaseGenzymeIn use
ISScheieα -iduronidaselaronidaseGenzymeIn use
IIHunterIduronidase sulfataseidursulfase



(Elaprase)



ShireIn use
III ‡ Sanfilippo AHeparan sulfatase.........
Sanfilippo BN- acetylglucosaminidase.........
Sanfilippo CAcetyl CoA glucosamine acetyltransferase.........
Sanfilippo DN -acetylglucosamine-6-sulfatase.........
IVMorquio AN-acetylgalactosamine-6-sulfataseelosulfase alfa (Vimizim)BioMarinIn use
Morquio Bβ -galactosidase.........
VIMaroteaux-LamyN -acetylhexosamine-4-sulfatasegalsulfase (Naglazyme)BioMarinIn use
VIISly § β -glucuronidase.........
IXHyaluronidase Deficiency || |Hyaluronidase.........
GSDIIPompeAcid α -glucosidasealglucosidase (Myozyme)GenzymeIn use
Note. This table represents the status of enzyme replacement therapy as of February 2014. Progress occurs on a daily basis; please investigate further for the most up to date information.
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.